+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


UK Respiratory Drug Market 2019-2025

  • ID: 5013522
  • Report
  • February 2020
  • Region: United Kingdom
  • Orion Market Research Private Limited
until Dec 31st 2021


  • Air Liquide S.A.
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co.
  • Omron Healthcare Inc.
  • Pulmatrix Inc.
UK Respiratory Drug Market Size, Share & Trends Analysis Report by Route of Administration (Oral, Injectable, and Inhalable), by Application (Asthma and Chronic Obstructive Pulmonary Disease (COPD)), by End-User (Homecare and Hospitals and Clinics) and Forecast 2019-2025.

UK respiratory drug market was $11.1 billion in 2018 and is anticipated to grow at a substantial rate of 7.0% during the forecast period. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors augmenting the growth of the respiratory drug market in Europe. Respiratory drugs are used for treatment of patient from asthma attacks and other respiratory ailments. As the prevalence of asthma and other diseases increases across UK, the demand of respiratory drugs is also expected to increase for treatment purposes. As per International Monetary Fund GDP of the country was $2.9 trillion in 2017. UK comprises of England, Scotland, Wales and Northern Ireland. Total population of the country in 2017 was 65 million, out of which about 18% are of geriatric population. Mortalities related to asthma and COPD are high in UK and due to these a significant investment by government and people can be forecast in the near future.

The UK respiratory drug market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, injectable, and inhalable. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the nation. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing respiratory drug to cater to a wide range of customers within and outside the region. The major players of the UK respiratory drug market include AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, F. Hoffmann-La Roche Ltd. and Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.

Research Methodology

The market study of the UK respiratory drug market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors.

Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for respiratory drug manufacturers, inhalers manufacturing companies, contract research organizations (CROs), healthcare sector, market research firms, and government organizations, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. UK Respiratory Drug Market Research and Analysis by Route of Administration
2. UK Respiratory Drug Market Research and Analysis by Application
3. UK Respiratory Drug Market Research and Analysis by End-User

The Report Covers:
  • Comprehensive research methodology of the UK respiratory drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the UK respiratory drug market.
  • Insights about market determinants which are stimulating the UK respiratory drug market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown


  • Air Liquide S.A.
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co.
  • Omron Healthcare Inc.
  • Pulmatrix Inc.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. UK Respiratory Drug Market by Route of Administration
5.1.1. Oral
5.1.2. Injectable
5.1.3. Inhalable
5.2. UK Respiratory Drug Market by Application
5.2.1. Asthma
5.2.2. Chronic Obstructive Pulmonary Disease (COPD)
5.3. UK Respiratory Drug Market by End-User
5.3.1. Homecare
5.3.2. Hospitals and Clinics

6. Company Profiles
6.1. Air Liquide S.A.
6.2. Aradigm Corp.
6.3. AstraZeneca PLC
6.4. Baxter International Inc.
6.5. Boehringer Ingelheim International GmbH
6.6. F. Hoffmann-La Roche Ltd.
6.7. GlaxoSmithKline PLC
6.8. Merck & Co.
6.9. Novartis AG
6.10. Omron Healthcare Inc.
6.11. Pfizer Inc.
6.12. Pulmatrix Inc.
6.13. ResMed Corp.
6.14. Savara, Inc.
6.15. Sunovion Pharmaceuticals
6.16. Takeda Pharmaceutical Company Ltd.
6.17. Teva Pharmaceuticals Industries Ltd.
Note: Product cover images may vary from those shown
  • Air Liquide S.A.
  • Aradigm Corp.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Merck & Co.
  • Novartis AG
  • Omron Healthcare Inc.
  • Pfizer Inc.
  • Pulmatrix Inc.
  • ResMed Corp.
  • Savara, Inc.
  • Sunovion Pharmaceuticals
  • Takeda Pharmaceutical Company Ltd.
  • Teva Pharmaceuticals Industries Ltd.
Note: Product cover images may vary from those shown